# Endovascular Intervention Among Patients Complicated by Acute Inferior Deep Venous Thrombosis: A Single‐Center Retrospective Cohort Study From Vietnam

**Authors:** Van Nut Lam, Duc Tin Le, Manh Hung Nguyen, Thuy Vy Tran Thi, Phuc Nhon Nguyen

PMC · DOI: 10.1155/ijvm/4819877 · International Journal of Vascular Medicine · 2026-03-08

## TL;DR

This study evaluates endovascular treatment for deep vein thrombosis in Vietnam, finding it effective with manageable risks and identifying factors linked to post-treatment complications.

## Contribution

The study provides real-world evidence on endovascular intervention outcomes for acute inferior DVT in a Vietnamese cohort and identifies risk factors for postthrombotic syndrome.

## Key findings

- Endovascular intervention showed reduced symptoms and manageable complications in most patients.
- Comorbidities and high BMI significantly increased the risk of postthrombotic syndrome.
- Most patients experienced mild or no postthrombotic syndrome following treatment.

## Abstract

The study was aimed at evaluating the efficacy, safety, and outcomes of endovascular intervention (EVT) among patients with acute inferior deep vein thrombosis (DVT), as well as revealing the risk factors associated with postthrombotic syndrome (PTS) in these patients.

This retrospective study was conducted at the Department of Vascular Surgery, C.R. Hospital, Vietnam. The study enrolled all the patients diagnosed with acute lower limb DVT and underwent EVT (thromboaspiration, thrombolysis, balloon angioplasty, and stent placement) between January 2017 and December 2022. All the patients were recorded with treatment outcomes, postinterventional complications, and factors relating to PTS on the follow‐up at 1 week and at 1 month after intervention.

A total of 37 patients met the inclusion criteria. Baseline characteristics included a mean age of 55.8 ± 13.3 years, female sex (75.5%), body mass index (BMI) ≥ 23 kg/m2 (63.2%), and inferior DVT on the left side (91.9%). Location of thrombus was noted at the iliac vein (97.3%), the femoral vein (70.3%), and the popliteal vein (97.3%). Postoperative length of stay was 5.5 ± 2.7 days, and clinical symptoms reduced in 2.5 ± 0.9 days. There were two cases of bleeding at the interventional site and two cases of death. Partial stenosis at 1 week and 1 month regarding the iliac vein, the femoral vein, and the popliteal vein was 71.4% and 54.3%, 14.3% and 37.1%, and 20.0% and 40.0%, respectively. None of the cases were observed with complete stenosis. In addition, 62.9% of cases reported no PTS. 37.1% of cases were noted with mild PTS. Advanced age, high BMI, duration time of thrombolysis, and underlying diseases were all associated factors relating to PTS. Noticeably, comorbidities and overweight/obesity increased 18.7‐ and 17.33‐fold risk of PTS (p < 0.05), respectively.

EVT is an acceptable alternative method in the treatment of acute inferior DVT. A decision‐making of EVTs for acute lower limb DVT should be implemented after assessment of risk factors in large centers with professional conditions and facilities.

## Linked entities

- **Diseases:** postthrombotic syndrome (MONDO:0005928)

## Full-text entities

- **Genes:** FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}
- **Diseases:** overweight (MESH:D050177), hypercoagulability (MESH:D019851), venous leg ulcer (MESH:D014647), intracranial hemorrhage (MESH:D020300), May-Thurner syndrome (MESH:D062108), bleeding (MESH:D006470), obese (MESH:D009765), PTS (MESH:D054070), stenosis (MESH:D003251), inherited (MESH:D030342), fever (MESH:D005334), pulmonary embolism (MESH:D011655), pain (MESH:D010146), dyslipidemia (MESH:D050171), venous obstruction (MESH:D006502), trauma (MESH:D014947), venous reflux (MESH:D005764), hematoma (MESH:D006406), edema (MESH:D004487), chronic kidney disease (MESH:D051436), inferior vena cava occlusion (MESH:C563013), diabetes (MESH:D003920), venous valvular reflux (MESH:D006349), venous lesions (MESH:D020520), cancer (MESH:D009369), lower extremity artery embolism (MESH:D004617), Type II diabetes (MESH:D003924), fibroids (MESH:D007889), RPVT (MESH:D018365), renal diseases (MESH:D007674), coma (MESH:D003128), hypertension (MESH:D006973), arterial occlusion (MESH:D001157), death (MESH:D003643), PCDT (MESH:D055499), venous thromboembolic (VTE) disorder (MESH:D054556), cerebral hemorrhage (MESH:D002543), restenosis (MESH:D023903), popliteal vein thrombosis (MESH:D012170), in-stent thrombosis (MESH:D013927), DVT (MESH:D020246), acute inferior deep vein thrombosis (MESH:D056989), vein dilation (MESH:D002311), coagulation (MESH:D001778), thrombocytopenia (MESH:D013921), ischemic heart disease (MESH:D017202), cerebral infarction (MESH:D002544)
- **Chemicals:** aspirin (MESH:D001241), blood sugar (MESH:D001786), ticlopidine (MESH:D013988), LMWH (MESH:D006495), Heparin (MESH:D006493), CaVenT (-), lidocaine (MESH:D008012)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12968076/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12968076/full.md

## References

24 references — full list in the complete paper: https://tomesphere.com/paper/PMC12968076/full.md

---
Source: https://tomesphere.com/paper/PMC12968076